Nuveen LLC Makes New $938,000 Investment in Omeros Corporation $OMER

Nuveen LLC purchased a new position in shares of Omeros Corporation (NASDAQ:OMER) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 114,057 shares of the biopharmaceutical company’s stock, valued at approximately $938,000. Nuveen LLC owned approximately 0.20% of Omeros at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the business. Invesco Ltd. boosted its stake in Omeros by 169.1% during the first quarter. Invesco Ltd. now owns 87,044 shares of the biopharmaceutical company’s stock worth $716,000 after buying an additional 54,696 shares in the last quarter. Deutsche Bank AG boosted its stake in shares of Omeros by 4.9% in the 1st quarter. Deutsche Bank AG now owns 42,019 shares of the biopharmaceutical company’s stock valued at $345,000 after purchasing an additional 1,973 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Omeros by 3.0% in the 1st quarter. Vanguard Group Inc. now owns 3,237,256 shares of the biopharmaceutical company’s stock valued at $26,610,000 after purchasing an additional 95,599 shares in the last quarter. Harbour Investments Inc. boosted its stake in shares of Omeros by 51.9% in the 1st quarter. Harbour Investments Inc. now owns 9,218 shares of the biopharmaceutical company’s stock valued at $76,000 after purchasing an additional 3,149 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in shares of Omeros by 2.2% in the 1st quarter. Bank of New York Mellon Corp now owns 151,062 shares of the biopharmaceutical company’s stock valued at $1,242,000 after purchasing an additional 3,321 shares in the last quarter. Institutional investors and hedge funds own 48.79% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. HC Wainwright restated a “buy” rating and issued a $9.00 target price on shares of Omeros in a research note on Friday, June 27th. Wall Street Zen downgraded shares of Omeros from a “hold” rating to a “sell” rating in a research note on Friday, June 27th. Needham & Company LLC restated a “hold” rating on shares of Omeros in a research note on Friday, August 15th. Finally, D. Boral Capital restated a “buy” rating and issued a $36.00 target price on shares of Omeros in a research note on Friday, August 15th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $18.00.

Omeros Stock Down 1.7%

Shares of NASDAQ OMER opened at $4.16 on Tuesday. The firm’s 50-day simple moving average is $3.78 and its 200 day simple moving average is $5.40. The company has a market cap of $283.13 million, a price-to-earnings ratio of -1.97 and a beta of 2.37. Omeros Corporation has a 12-month low of $2.95 and a 12-month high of $13.60.

Omeros (NASDAQ:OMER) last issued its quarterly earnings results on Thursday, August 14th. The biopharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.02. The company had revenue of $28.60 million for the quarter, compared to analyst estimates of $0.31 million. On average, equities analysts expect that Omeros Corporation will post -3.09 earnings per share for the current year.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.